Pimicotinib
As of the edition of 20 October 2026, Pimicotinib is a small molecule: marketed, first approved in 2026 (CA); acts on CSF1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Pimjetmi
- First approved
- 12 June 2026 (CA)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- EMD SERONO, A DIVISION OF EMD INC., CANADA
- Registered trials
- 14, 0 stopped early
- Disease areas
- Cancer; Bones, joints and muscles; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF1R | Macrophage colony-stimulating factor 1 receptor | P07333 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 7 | 2 | 0 |
| Phase 2 | 4 | 0 | 4 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Abbisko Therapeutics | Lead sponsor of trials | 2020 to now |
| Merck Healthcare KGaA | Lead sponsor of trials | 2026 to now |